Zacks Research Has Pessimistic View of Medifast Q2 Earnings

Medifast, Inc. (NYSE:MED) – Research analysts at Zacks Research lowered their Q2 2025 earnings per share estimates for Medifast in a note issued to investors on Monday, November 25th. Zacks Research analyst A. Mohta now forecasts that the specialty retailer will post earnings per share of $0.29 for the quarter, down from their prior estimate of $0.37. The consensus estimate for Medifast’s current full-year earnings is $1.51 per share. Zacks Research also issued estimates for Medifast’s Q3 2025 earnings at $0.34 EPS, Q4 2025 earnings at $0.38 EPS, Q1 2026 earnings at $0.42 EPS and Q2 2026 earnings at $0.43 EPS.

Medifast (NYSE:MED) last posted its quarterly earnings data on Monday, November 4th. The specialty retailer reported $0.35 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.50. The business had revenue of $140.16 million during the quarter, compared to the consensus estimate of $135.45 million. Medifast had a return on equity of 15.98% and a net margin of 1.09%. During the same period last year, the company earned $2.12 earnings per share.

Separately, DA Davidson upgraded Medifast from an “underperform” rating to a “neutral” rating and raised their price target for the company from $16.50 to $17.00 in a research note on Tuesday, November 5th.

Medifast Stock Down 1.6 %

MED stock opened at $18.32 on Wednesday. The company has a quick ratio of 2.55, a current ratio of 3.11 and a debt-to-equity ratio of 0.06. The business has a 50 day moving average price of $18.48 and a two-hundred day moving average price of $19.83. The company has a market cap of $200.42 million, a price-to-earnings ratio of 27.76 and a beta of 1.13. Medifast has a twelve month low of $17.07 and a twelve month high of $76.42.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the business. nVerses Capital LLC boosted its stake in Medifast by 54.5% in the 2nd quarter. nVerses Capital LLC now owns 1,700 shares of the specialty retailer’s stock valued at $37,000 after purchasing an additional 600 shares during the period. Centiva Capital LP boosted its stake in Medifast by 6.3% in the 3rd quarter. Centiva Capital LP now owns 15,238 shares of the specialty retailer’s stock valued at $292,000 after purchasing an additional 898 shares during the period. Quarry LP boosted its stake in Medifast by 592.7% in the 2nd quarter. Quarry LP now owns 2,667 shares of the specialty retailer’s stock valued at $58,000 after purchasing an additional 2,282 shares during the period. Price T Rowe Associates Inc. MD boosted its stake in Medifast by 21.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 13,828 shares of the specialty retailer’s stock valued at $530,000 after purchasing an additional 2,472 shares during the period. Finally, Swedbank AB bought a new stake in Medifast in the 1st quarter valued at $115,000. 95.51% of the stock is currently owned by institutional investors.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.